Lang Matthew has filed 13 insider transactions across 3 companies since August 2023.
Most recent transaction: a grant/award of 184614 shares of Structure Therapeutics Inc. ($GPCR) on April 15, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 15, 2026 | Structure Therapeutics Inc. | $GPCR | Lang Matthew | COO & GC | A | Ordinary Shares | 184614 | $0.00 | 184,614.0000 | 177,596,000 | 9999.99% | 0.10% |
| April 15, 2026 | Structure Therapeutics Inc. | $GPCR | Lang Matthew | COO & GC | A | Share option (right to buy) | 223776 | $0.00 | 223,776.0000 | 177,596,000 | 9999.99% | 0.13% |
| Nov. 13, 2025 | Metsera, Inc. | $MTSR | Lang Matthew | CHIEF LEGAL OFFICER | D | Common Stock | 12500 | $0.00 | 0.0000 | 105,376,189 | 100.00% | 0.01% |
| Nov. 13, 2025 | Metsera, Inc. | $MTSR | Lang Matthew | CHIEF LEGAL OFFICER | A | Restricted Stock Unit | 12500 | $0.00 | 12,500.0000 | 105,376,189 | 9999.99% | 0.01% |
| Nov. 13, 2025 | Metsera, Inc. | $MTSR | Lang Matthew | CHIEF LEGAL OFFICER | D | Stock Option (right to buy) | 46875 | $0.00 | 0.0000 | 105,376,189 | 100.00% | 0.04% |
| Nov. 13, 2025 | Metsera, Inc. | $MTSR | Lang Matthew | CHIEF LEGAL OFFICER | D | Stock Option (right to buy) | 325000 | $0.00 | 0.0000 | 105,376,189 | 100.00% | 0.31% |
| May 20, 2025 | Metsera, Inc. | $MTSR | Lang Matthew | Chief Legal Officer | A | Stock Option (Right to Buy) | 46875 | $0.00 | 46,875.0000 | 105,050,219 | 9999.99% | 0.04% |
| Feb. 10, 2025 | Lyell Immunopharma, Inc. | $LYEL | Lang Matthew | Chief Business Officer | A | Option (right to buy) | 450000 | $0.00 | 450,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Lyell Immunopharma, Inc. | $LYEL | Lang Matthew | Chief Business Officer | A | Common Stock | 112500 | $0.00 | 162,500.0000 | 0 | 225.00% | 0.00% |
| Feb. 10, 2025 | Lyell Immunopharma, Inc. | $LYEL | Lang Matthew | Chief Business Officer | A | Option (right to buy) | 56250 | $0.00 | 56,250.0000 | 0 | 9999.99% | 0.00% |
| Feb. 9, 2024 | Lyell Immunopharma, Inc. | $LYEL | Lang Matthew | Chief Business Officer | A | Option (right to buy) | 500000 | $0.00 | 500,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 9, 2024 | Lyell Immunopharma, Inc. | $LYEL | Lang Matthew | Chief Business Officer | A | Common Stock | 50000 | $0.00 | 50,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 10, 2023 | Lyell Immunopharma, Inc. | $LYEL | Lang Matthew | Chief Business Officer | A | Option (right to buy) | 2250000 | $0.00 | 2,250,000.0000 | 0 | 9999.99% | 0.00% |